MFOLFOX6 clinical trials
MFOLFOX6 is named as an intervention in 35 current clinical trials in our China, USA, Australia, Germany, South Korea, France, UK, Spain, Italy, Belgium, Canada, Taiwan, Egypt, Japan, Ireland, Netherlands, Denmark, Poland, Austria, Czechia, Portugal, Brazil, Mexico, Singapore and Israel registers. 21 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (3). The most-studied condition is Colorectal Cancer.
Patient leaflets for MFOLFOX6
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of MFOLFOX6
35 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with MFOLFOX6
47 conditionsAll 47 conditions
| Condition (as registered) | Trials |
|---|---|
| Colorectal Cancer | 8 |
| Rectal Cancer | 4 |
| Metastatic Colorectal Cancer | 2 |
| Non-Small Cell Lung Cancer | 2 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 2 |
| CRC (Colorectal Cancer) | 2 |
| Cancer | 2 |
| Colorectal Cancer (CRC) | 2 |
| Metastatic Colorectal Cancer (CRC) | 2 |
| Advanced Colorectal Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Metastatic Gastric Adenocarcinoma | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Advanced Solid Tumors | 1 |
| NSCLC | 1 |
| CRC | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| PDAC | 1 |
| Advanced Cancer | 1 |
| Gastric Cancer | 1 |
| Gastroesophageal-junction Cancer | 1 |
| Pancreatic Cancer | 1 |
| Left-sided Colorectal Cancer | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| Capecitabine | 1 |
| Cetuximab | 1 |
| Solid Tumors | 1 |
| pMMR/MSS Adenocarcinoma of the Colon or Rectum | 1 |
| Rectal Adenocarcinoma | 1 |
| High-Risk Cancer | 1 |
| MSS | 1 |
| Unresectable Advanced or Metastatic Colorectal Cancer | 1 |
| Unresectable/Metastatic Colorectal Cancer | 1 |
| Colorectal Cancer Liver Metastasis | 1 |
| Metastatic HER2 Positive Gastroesophageal Junction Cancer | 1 |
| Colorectal Cancer (Locally Advanced or Metastatic) | 1 |
| Colorectal Cancer Microsatellite Stable (MSS) | 1 |
| Patients With Resected Stage II Colon Cancer | 1 |
| Rectum Cancer | 1 |
| Solid Tumor | 1 |
| Locally Advanced Solid Tumor | 1 |
| Colo-rectal Cancer | 1 |
| Colon Cancer | 1 |
| Colon Carcinoma | 1 |
| Esophagus Adenocarcinoma | 1 |
| Colon Cancer Stage III | 1 |
Sponsors
lead sponsor per trial+ 17 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about MFOLFOX6 trials
How many clinical trials are testing MFOLFOX6?
35 current trials in our China, USA, Australia, Germany, South Korea, France, UK, Spain, Italy, Belgium, Canada, Taiwan, Egypt, Japan, Ireland, Netherlands, Denmark, Poland, Austria, Czechia, Portugal, Brazil, Mexico, Singapore and Israel registers name MFOLFOX6 (also registered as MFOLFOX-6) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are MFOLFOX6 trials recruiting patients?
Yes. 21 of the 35 trials are recruiting: 10 with sites in China, 7 with sites in USA, 4 with sites in Australia, 2 with sites in Germany, 2 with sites in South Korea, 2 with sites in France, 1 with sites in UK, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Taiwan, 1 with sites in Egypt and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors MFOLFOX6 clinical trials?
Sun Yat-sen University (3), Dominik Paul Modest (2), Mirati Therapeutics Inc (1) and Boehringer Ingelheim (1), among 32 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there MFOLFOX6 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MFOLFOX6 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MFOLFOX6 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MFOLFOX6 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.